| 重组链激酶对急性心肌梗死溶栓治疗临床观察 |
| |
| 引用本文： | 刘卓敏,王晋军.重组链激酶对急性心肌梗死溶栓治疗临床观察[J].山西医药杂志,1999,28(3):190-191. |
| |
| 作者姓名： | 刘卓敏 王晋军 |
| |
| 作者单位： | 山西省心血管疾病研究所 |
| |
| 摘 要： | 目的：观察溶栓新药重组链激酶（ｒ－ＳＫ）在急性心肌梗死（ＡＭＩ）静脉溶栓治疗中的临床疗效和不良反应。方法：采用平行随机单盲对照的研究方法，以尿激酶（ＵＫ）为对照比较ｒ－ＳＫ对ＡＭＩ的溶栓治疗效果和不良反应。结果：ｒ－ＳＫ１５０万Ｕ对ＡＭＩ的溶栓再通率为８４．４％，而ＵＫ１５０万Ｕ仅为５６．７％（Ｐ＜０．０５）。不良反应除发冷外其他方面两组无差异。结论：国产ｒ－ＳＫ是一个血管再通率高，不良反应及出血并发症低，安全有效的溶栓药物。
|
| 关 键 词： | 急性心肌梗死 重组链激酶 溶栓治疗 |
CLLNICAL TRIAL OF RECOMBINANT STREPTOKINASE (r SK) IN ACUTE MYOCARDIAL INFARCTION |
| |
| Liu Zhuomin,Wang Jinjun,Wang Xutai,Li Yunqian.CLLNICAL TRIAL OF RECOMBINANT STREPTOKINASE (r SK) IN ACUTE MYOCARDIAL INFARCTION[J].Shanxi Medical Journal,1999,28(3):190-191. |
| |
| Authors: | Liu Zhuomin Wang Jinjun Wang Xutai Li Yunqian |
| |
| Abstract: | Objective:To observe the efficacy and safety of intravenous recombinant streptokinase (r SK) in treatment of acute myocardial infarction (AMI).Methods:In this single blind,randomized,parallel controlled study,we compared the efficacy and safety of r SK with those of urokinase (UK).Results:The reperfusion rate of r SK 1.5 million units was 84.4% but that of UK 1.5 million units was only 56.7% (P<0.05).Complications were similiar between two groups except feeling cold.Conclusion:China made r SK is a safe and effective thrombolytic agent. |
| |
| Keywords: | acute myocardial infarction recombinant streptokinase thrombolytic therapy |
| 本文献已被 CNKI 维普 等数据库收录！ |
